PDL BioPharma (PDL BioPharma) LT-Debt-to-Total-Asset : 0.03 (As of Jun. 2020)

View and export this data going back to 1992. Start your Free Trial

What is PDL BioPharma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PDL BioPharma's long-term debt to total assests ratio for the quarter that ended in Jun. 2020 was 0.03.

PDL BioPharma's long-term debt to total assets ratio declined from Jun. 2019 (0.14) to Jun. 2020 (0.03). It may suggest that PDL BioPharma is progressively becoming less dependent on debt to grow their business.

PDL BioPharma LT-Debt-to-Total-Asset Historical Data

The historical data trend for PDL BioPharma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDL BioPharma LT-Debt-to-Total-Asset Chart

PDL BioPharma Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.24

0.20

0.10

0.14

0.05

PDL BioPharma Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.14	0.15	0.05	0.02	0.03

PDL BioPharma LT-Debt-to-Total-Asset Calculation

PDL BioPharma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )	/	Total Assets (A: Dec. 2019 )
	=	37.95	/	716.119
	=	0.05

PDL BioPharma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2020 is calculated as

LT Debt to Total Assets (Q: Jun. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2020 )	/	Total Assets (Q: Jun. 2020 )
	=	13.507	/	520.656
	=	0.03

PDL BioPharma (NAS:PDLI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PDL BioPharma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of PDL BioPharma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PDL BioPharma (PDL BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDL BioPharma Inc (NAS:PDLI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

932 Southwood Boulevard, Incline Villiage, NV, USA, 89451

Website

http://www.pdl.com

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Medical Devices, Strategic Positions, Pharmaceutical and Income Generating Assets, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Executives

David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
John Peter Mclaughlin	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Dominique Monnet	officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410
Christopher Lewis Stone	officer: VP, Gen. Counsel & Secretary	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Alan Lee Bazaar	director	9 BEDFORD ROAD, KATONAH NY 10536
Natasha Hernday	director	932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Edward Imbrogno	officer: VP Finance, CAO and Acting CFO	932 SOUTHWOOD BLVD. INCLINE VILLAGE NV 89451
Jill M. Jene	officer: VP, Business Development	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Harold E Selick	director
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304
Paul W Sandman	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Peter S Garcia	officer: Vice President, CFO	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jody S Lindell	director	2536 FILLMORE ST., SAN FRANCISCO CA 94115
Paul R Edick	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010